Startseite>>Signaling Pathways>> Cardiovascular>> Vasodilation>>Quinapril-d5

Quinapril-d5 (Synonyms: CI-906-d5)

Katalog-Nr.GC48513

An internal standard for the quantification of quinapril

Products are for research use only. Not for human use. We do not sell to patients.

Quinapril-d5 Chemische Struktur

Cas No.: 1279029-79-6

Größe Preis Lagerbestand Menge
500µg
170,00 $
Auf Lager
1mg
321,00 $
Auf Lager
5mg
1.188,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Quinapril-d5 is intended for use as an internal standard for the quantification of quinapril by GC- or LC-MS. Quinapril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor quinaprilat.1,2 In vivo, quinapril (3 mg/kg) reduces mean arterial pressure in renal hypertensive and spontaneously hypertensive rats.2 It inhibits angiotensin I-induced pressor responses in normotensive rats and dogs. Quinapril (10-200 mg/kg) prevents left ventricular heart failure in CHF 14.6 cardiomyopathic hamsters. Formulations containing quinapril have been used in the treatment of hypertension, heart failure, and diabetic nephropathy.

1.Vago, T., Bevilacqua, M., Conci, F., et al.Angiotensin converting enzyme binding sites in human heart and lung: Comparison with rat tissuesBr. J. Pharmacol.107(3)821-825(1992) 2.Kaplan, H.R., Taylor, D.G., and Olson, S.C.Quinapril: Overview of preclinical dataClin. Cardiol.13(6 Suppl. 7)VII6-VII12(1990)

Bewertungen

Review for Quinapril-d5

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Quinapril-d5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.